<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04653818</url>
  </required_header>
  <id_info>
    <org_study_id>0304763</org_study_id>
    <nct_id>NCT04653818</nct_id>
  </id_info>
  <brief_title>HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial</brief_title>
  <acronym>RCT</acronym>
  <official_title>Does Directly Acting Antivirals Usage Affect HCV Related Hepatocellular Carcinoma Recurrence After Percutaneous Ablation: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data regarding hepatocellular carcinoma (HCC) recurrence after directly acting antivirals&#xD;
      (DAAs) given for hepatitis C virus treatment are contradictory. Surprisingly, some studies&#xD;
      reported that DAAs are accompanied with higher HCC recurrence. But, other studies showed no&#xD;
      rise or even decrease in HCC recurrence. Most of these studies were retrospective and some&#xD;
      were non-randomized prospective studies. Here investigators aim to perform a randomized&#xD;
      controlled trial to study this issue.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 5, 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HCC recurrence</measure>
    <time_frame>1 year after HCC ablation procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in Child-Pugh scores over time</measure>
    <time_frame>1 year from HCC ablation procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Hepatitis C</condition>
  <condition>Neoplasm Recurrence</condition>
  <condition>Treatment Complication</condition>
  <arm_group>
    <arm_group_label>DAAs group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Those with complete HCC ablation who will start sofosbuvir / velpatasvir aiming to eradicate HCV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Postponed DAAs group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Those who will not start DAAs within the 12 months follow up from HCC ablation procedure. Patients of this group will receive DAAs provided that there is no HCC recurrence after the end of 1 year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Velpatasvir/Sofosbuvir</intervention_name>
    <description>sofosbuvir / velpatasvir will be given for 12 weeks aiming to eradicate HCV. Ribavirin will be added for Child-Pugh B patients or treatment will be extended for 24 weeks for those who are Ribavirin intolerant.</description>
    <arm_group_label>DAAs group</arm_group_label>
    <arm_group_label>Postponed DAAs group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Child-Pugh A and B subjects with hepatitis C related &lt; 5 cm single or up to 3&#xD;
             hepatocellular carcinomas without any vascular or extrahepatic involvement&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those with positive HBsAg, history of alcohol consumption, patients with other known&#xD;
             causes of chronic liver disease, patients who have received previous DAAs for HCV and&#xD;
             patients who have received previous locoregional treatment for HCC will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Kamal, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lecturer of Internal Medicine and Hepatology, Faculty of Medicine, Alexandria University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed Kamal, MD,PhD</last_name>
    <phone>+201279734654</phone>
    <email>Ahmed.Kamal@alexmed.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alexandria University, Faculty of Medicine</name>
      <address>
        <city>Alexandria</city>
        <zip>21131</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Kamal</last_name>
      <phone>01279734654</phone>
      <email>Ahmed.Kamal@alexmed.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 28, 2020</study_first_submitted>
  <study_first_submitted_qc>November 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>December 9, 2020</last_update_submitted>
  <last_update_submitted_qc>December 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>Ahmed Kamal</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Velpatasvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

